Other clinical studies have been designed to test the ability of IL-15 to increase antibody-dependent cellular cytotoxicity (ADCC) effects, using IL-15 in combination with tumour-targeting monoclonal antibodies such as alemtuzumab (NCT02689453) or rituximab (NCT02384954). This evidence concerns the gene IL15 and neoplasm.